CN112438393A - Composition with auxiliary tumor prevention effect - Google Patents

Composition with auxiliary tumor prevention effect Download PDF

Info

Publication number
CN112438393A
CN112438393A CN201910799644.4A CN201910799644A CN112438393A CN 112438393 A CN112438393 A CN 112438393A CN 201910799644 A CN201910799644 A CN 201910799644A CN 112438393 A CN112438393 A CN 112438393A
Authority
CN
China
Prior art keywords
vitamin
composition
selenium
essence
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910799644.4A
Other languages
Chinese (zh)
Inventor
张磊
徐希平
秦献辉
姜城子
白洁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fulette Shenzhen Precision Nutrition Food Group Co ltd
AUSA PHARMED Ltd
Original Assignee
Fulette Shenzhen Precision Nutrition Food Group Co ltd
AUSA PHARMED Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fulette Shenzhen Precision Nutrition Food Group Co ltd, AUSA PHARMED Ltd filed Critical Fulette Shenzhen Precision Nutrition Food Group Co ltd
Priority to CN201910799644.4A priority Critical patent/CN112438393A/en
Publication of CN112438393A publication Critical patent/CN112438393A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a composition consisting of vitamin A, vitamin D, vitamin E, selenium and proper auxiliary materials, wherein the content of the vitamin A is 160-800 mu g, the content of the vitamin D is 2-15 mu g, the content of the vitamin E is 5-150 mu g, and the content of the selenium is 10-100 mu g. The invention selects vitamins with exact functions, carries out scientific composition, has functional synergistic effect among the components, aims at middle-aged and elderly people, assists in preventing tumors, and embodies accurate nutritional characteristics.

Description

Composition with auxiliary tumor prevention effect
Technical Field
The invention relates to a composition, in particular to a composition capable of assisting middle-aged and elderly people in preventing tumors, and belongs to the field of big health.
Background
With the rapid development of social economy, the living environment of human beings is greatly improved, but the problem of aging of human mouth is increasingly prominent, and the health problems of middle-aged and elderly people become one of the key points of medical attention. After the disease is treated by middle-aged and old people, along with the gradual decline of the immune system function and the whole body function, the immune monitoring and removing function of the human body to tumor cells is reduced, and the human body is more easily affected by various external carcinogenic factors than the young, so the prevention of tumor diseases by middle-aged and old people needs to be considered.
The vitamin A acid (retinoic acid) has the functions of delaying or preventing precancerous lesion and preventing chemical carcinogenic agents, and particularly has good effect on epithelial tissue tumor clinically as an auxiliary therapeutic agent. Vitamin D can inhibit, treat or prevent various tumor cells in vivo, inhibit cancer promotion effect of chemical carcinogen, promote tumor regression, inhibit tumor metastasis and angiogenesis thereof, and prolong survival time. Many cellular enzymatic systems, mitochondrial electron transport, exposed to various environmental factors, may generate oxygen radicals and other free radicals, vitamin E, because of its lipid solubility, directly protects the cell membrane in the free radical detoxification defense system, preventing damage by free radicals or oxidants to polyunsaturated fatty acids, thiol-rich protein components, and the cytoskeleton and nucleic acids in the cell membrane. Selenium is a trace element necessary for human bodies and animal bodies, can effectively inhibit the proliferation of tumor cells, and can effectively enhance the disease resistance of human bodies under the synergistic action of vitamin E, protect the normal functions of human cells, thereby effectively reducing the risk of suffering from tumor diseases. Therefore, the vitamin A, the vitamin D, the vitamin E and the selenium are supplemented in a proper amount in a targeted manner, the cellular immunity can be regulated, the humoral immunity function can be enhanced, and the effect of auxiliary prevention and treatment of tumor diseases can be achieved.
Although many health care products combining various vitamins and trace elements exist in the market at present, most of the health care products play a role of a nutritional supplement, can be taken by various groups, and have very limited actual health care effect due to lack of pertinence and small dosage of a formula. Therefore, the present invention aims to develop a composition suitable for the middle-aged and elderly people to prevent tumors, select vitamins and trace elements with synergistic functions, and give a physiological sufficient amount to perform accurate nutrition to people with specific nutrient deficiency, thereby maximizing the health care function of the product.
Disclosure of Invention
The invention aims to provide a composition with the function of assisting in preventing tumor diseases of middle-aged and elderly people.
In order to achieve the purpose, the invention adopts the following technical scheme:
a composition for auxiliary prevention of tumor diseases comprises the following components:
(1) 160-800 μ g vitamin A;
(2) 2-15 μ g vitamin D;
(3) 5-150 μ g vitamin E;
(4) 10-100 μ g selenium;
(5) acceptable auxiliary materials.
In the composition, preferably, the content of vitamin A is 600-800 μ g, the content of vitamin D is 5-10 μ g, the content of vitamin E is 10-100 μ g, and the content of selenium is 20-100 μ g.
In the invention, the vitamin A source comprises vitamin A and beta-carotene of plant source.
In the present invention, the vitamin D includes vitamin D2 and vitamin D3.
In the present invention, the selenium includes inorganic selenium and organic selenium. Inorganic selenium includes but is not limited to sodium selenite, sodium selenate, organic selenium includes but is not limited to selenoprotein, selenium-rich yeast, selenate lipopolysaccharide, selenium-rich edible fungi, selenomethionine.
The composition can be prepared into oral preparations such as common tablets, chewable tablets, soft capsules, hard capsules, powder, granules and the like.
In the present invention, necessary and acceptable excipients are required to be added in order to prepare various suitable dosage forms. The adjuvants are selected from one or more of filler (dispersant), solubilizer, binder, disintegrating agent, lubricant, suspending agent, correctant, stabilizer, edible pigment, embedding substance, and coating premix.
The filler (dispersing agent) comprises one or more of starch, soluble starch, dextrin, maltodextrin, potato starch, corn starch, wheat starch, D-mannitol, calcium hydrophosphate, anhydrous calcium hydrophosphate, maltose, xylitol, sorbitol, microcrystalline cellulose, isomaltulose, milk powder, low-substituted hydroxypropyl cellulose, sucrose, glucose, lactose, pregelatinized starch, edible vegetable oil, polyethylene glycol and the like.
The suspending agent comprises one or more of beeswax, insect wax, lecithin, glyceryl monostearate, ethyl cellulose and the like, the wetting agent comprises purified water and ethanol, and the adhesive comprises one or more of hydroxypropyl methyl cellulose, povidone, hydroxypropyl cellulose, sodium carboxymethyl cellulose, starch, methyl cellulose, ethyl cellulose, gelatin, polyethylene glycol, pregelatinized starch, sucrose, glucose and the like.
The disintegrating agent comprises one or more of starch, carboxymethyl starch sodium, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, sodium bicarbonate, citric acid and the like.
The lubricant comprises one or more of magnesium stearate, stearic acid, talcum powder, silicon dioxide, hydrogenated vegetable oil, polyethylene glycol, sodium dodecyl sulfate, glyceryl behenate, sodium stearyl fumarate and the like.
The flavoring agent comprises one or more of fruit powder, edible essence, high-intensity sweetener, sour agent and the like, wherein the fruit powder comprises one or more of orange powder, lemon powder, cherry powder, apple powder, strawberry powder, kiwi fruit powder, orange powder, seabuckthorn fruit powder, green plum fruit powder, mango fruit powder, mulberry fruit powder, hawthorn fruit powder, watermelon fruit powder, pineapple fruit powder, blueberry fruit powder, honey peach fruit powder, hami melon fruit powder, grape fruit powder, vanilla fruit powder, pomegranate fruit powder, rose fruit powder and the like.
The edible essence comprises one or more of vanilla essence, sweet orange essence, milk essence, apple essence, grape essence, strawberry essence, pineapple essence, honey peach essence, hami melon essence, lemon essence, cherry essence, sweet corn essence, banana essence, grape essence, rose essence, blackcurrant essence, green apple essence, mango essence, green mango essence, orange essence, fragrant orange essence, snow pear essence, strawberry essence, green plum essence, blueberry essence, waxberry essence, grapefruit essence, pineapple essence, guava essence, passion fruit essence, kiwi fruit essence, cherry essence, kiwi fruit essence, watermelon essence, papaya essence, hami melon essence, durian essence, lychee essence, hawthorn essence, olive essence, mulberry essence and the like.
The sweetening agent comprises sucralose, aspartame, mogroside, neotame and stevioside, the acidulant comprises citric acid, malic acid, lactic acid, tartaric acid and fumaric acid, the edible pigment comprises caramel color, gardenia yellow, curcumin, chlorophyll, capsicum orange, capsanthin, grape skin red, carmine and aluminum lake thereof, sunset yellow and aluminum lake thereof, brilliant blue and aluminum lake thereof, indigo blue and aluminum lake thereof, beet red, natural amaranth, gardenia blue, vegetable carbon black, iron oxide red, black bean red, quinoline yellow, lycopene, monascus red, yellow iron oxide, cocoa shell color, safflower yellow, monascus yellow and the like.
The stabilizer comprises one or more of dibutyl hydroxy toluene (BHT), Butyl Hydroxy Anisol (BHA), vitamin C, L-ascorbic acid, tricalcium phosphate, magnesium phosphate, calcium carbonate and the like.
The embedding substance comprises one or more of beta-cyclodextrin, alpha-cyclodextrin, gamma-cyclodextrin, dextrin, starch, edible modified starch, sucrose, maltodextrin, gum arabic and the like.
The composition provided by the invention screens vitamins and trace elements with synergistic functions, carries out scientific composition according to the investigation result of early large clinical epidemics, and synergistically plays a role in preventing tumor diseases of middle-aged and elderly people by supplementing the composition of vitamin A, vitamin D, vitamin E and selenium with optimal dose. Vitamins are essential nutrients for the human body, and a long-term deficiency of vitamins increases the risk of developing neoplastic diseases. Clinical test results suggest that the risk of cancer is increased due to the lack of vitamin D, the risk of lung cancer is increased by 3 times due to the lack of vitamin A, and the risk of oral cancer, esophageal cancer, gastric cancer and intestinal cancer is increased due to the lack of vitamin E. The above epidemiological investigations provide a basis for the present compositions. In actual product development, the combination of vitamin A, D, E and selenium in a specific dosage through specific design and a large number of experimental screens shows an unexpected tumor prevention effect in experiments. Compared with the products sold in the market, the composition is a beneficial product with better and more accurate effect, the action effect of the composition is obviously stronger than the single application effect of the composition, and the composition is suitable for being prepared into food or nutritional supplements and can also be added into compound medicines as an effective component.
Embodiments of the present invention are further described below with reference to examples.
Detailed Description
Example 1: tablet preparation (1000 tablets amount) of the composition of the invention
The formula is as follows:
Figure BDA0002181954750000041
the preparation method comprises the following steps: mixing vitamin A, D, E and sodium selenite with microcrystalline cellulose and sodium dodecylbenzenesulfonate, and sieving; adding lactose, polyvinylpolypyrrolidone and passion fruit essence and mixing; adding magnesium stearate, mixing, and tabletting. The coating premix is prepared into solution, and tablets of the composition are prepared by coating the tablets.
Example 2: preparation of Soft capsules of the composition of the invention (1000 capsules)
The formula is as follows:
Figure BDA0002181954750000042
Figure BDA0002181954750000051
the preparation method comprises the following steps: adding Cera flava into soybean oil, heating at 50 deg.C to dissolve Cera flava, standing to room temperature, adding vitamin A, vitamin D, vitamin E, sodium selenite, and L-ascorbic acid into soybean oil to obtain suspension. Preparing gelatin solution from gelatin, purified water, grape skin red and p-hydroxybenzoate, pelleting the obtained suspension by a pelleting machine to obtain soft capsules, and carrying out shaping, washing and drying treatment to obtain the soft capsules of the composition.
Example 3: preparation of hard capsules (1000 granules) of the composition of the invention
The formula is as follows:
Figure BDA0002181954750000052
the preparation method comprises the following steps: mixing vitamin A, vitamin E, sodium selenate, stearic acid and 50% microcrystalline cellulose, sieving, adding lactose and magnesium stearate, mixing, filling by using a full-automatic capsule filling machine, and polishing to obtain the hard capsule of the composition.
In order to prove that the health-care product has the effect of preventing tumor diseases of middle-aged and elderly people, the following experiment is designed to mainly analyze the relationship between the levels of vitamin A, vitamin D and vitamin E in blood plasma and the tumor disease risk of middle-aged and elderly people with hypertension.
Example 4: preparation of granules of the composition according to the invention (1000 parts)
The formula is as follows:
Figure BDA0002181954750000061
the preparation method comprises the following steps: crushing sucrose and sieving with a 80-mesh sieve for later use; preparing binder from polyvidone K90 with 50% ethanol solution, adding vitamin A, vitamin E, and sodium selenate into the binder, and stirring. Adding sugar powder, maltodextrin, sodium carboxymethyl starch, Hami melon fruit powder and Hami melon essence, mixing, adding prepared adhesive containing vitamin A, vitamin E and sodium selenate to prepare soft material, granulating with 24-mesh sieve, drying at 50 deg.C for 2 hr, and grading with 24-mesh sieve to obtain the granule of the composition.
Example 5: chewable tablet preparation (1000 tablets amount) of the composition of the invention
The formula is as follows:
Figure BDA0002181954750000062
Figure BDA0002181954750000071
the preparation method comprises the following steps: preparing hydroxypropyl methylcellulose into adhesive with purified water, adding vitamin A, E into the adhesive, and stirring. Mixing sodium selenite with microcrystalline cellulose, sieving, adding stevioside, pineapple essence, milk powder and xylitol, mixing, adding a prepared binding agent containing vitamin A to prepare a soft material, granulating by using a 24-mesh sieve, drying for 2 hours at 55 ℃, granulating by using the 24-mesh sieve, adding magnesium stearate, mixing, and tabletting to obtain the chewable tablet of the composition.
Example 6: influence of vitamin A, vitamin D, vitamin E and trace element selenium deficiency on primary liver cancer rats
Wistar rats, male, 80, 150-170 g. Feeding conditions are as follows: the room temperature is 21-25 ℃, the relative humidity is 40-60%, and the light and the dark alternate between 12h and 12 h. 4 per cage, free food intake, water, change bedding every other day.
After 1 week of adaptive feeding, rats were randomly divided into a normal group (normal feed feeding), a deficient group (feed deficient in vitamin a, vitamin D, vitamin E, trace element selenium), a composition group (feed deficient in vitamin a, vitamin D, vitamin E, trace element selenium) and 20 animals per group. The formula of each group of feed is as follows:
TABLE 1 Experimental animal feed formulation (g/kg)
Figure BDA0002181954750000072
Figure BDA0002181954750000081
The method adopts intraperitoneal injection of diethyl nitrosamine to model primary liver cancer of a rat, and specifically comprises the following steps: except for the normal group, each group was intraperitoneally injected with diethylnitrosamine (40mg/Kg) 1 time/week for 12 consecutive weeks. Normal group injected with normal saline of the same volume for 1 time/week for 12 weeks; composition groups the composition of example 1 (VA + VD + VE + Se) (80+1.5+15+10) ug/kg was administered by gavage for 12 consecutive weeks during the entire molding cycle (80+1.5+15+ 10).
And (5) observing and recording the death condition of the rat in the experimental process, and calculating the survival rate. After the 12 week-end dosing, fasting was performed for 12 hours, and abdominal aorta was opened to collect blood and the rats were sacrificed after pentobarbital sodium anesthesia. And storing blood samples in an EDTA anticoagulation tube and an inert separation gel procoagulant tube respectively for subsequent determination. Picking up spleen and weighing and recording; the general condition of the liver of each group of rats is visually observed, and whether cancer nodules appear or not.
The experimental results are as follows: the rats in the normal group have good growth condition, obvious weight gain, glossy hair and normal drinking water. The ADESe deficient rats began to eat significantly less at week 3 than the normal rats, had dull hair, was slow to lose, or gain weight, and died first at week 5. Rats in the cancer model group started to eat significantly less, lazy and dull hair at week 5 and died at week 1 at week 6. The rats are extremely thin before death, have hair loss and lassitude, cannot eat and drink at the later stage, are compressed, and show a cachexia state. The composition group had less food intake than the normal group, lacked luster, lost motion, lost weight or increased slowly, and the composition group had the first death at week 10.
TABLE 2 survival Rate of rats in each group
Figure BDA0002181954750000082
The survival rate of each group is found by statistical analysis, the survival rate of the ADESe-deficient group is lower than that of the cancer model group, and the composition has better anti-cancer effect and higher survival rate.
TABLE 3 incidence of tumors in each group
Figure BDA0002181954750000091
The statistics of the tumor incidence of each group shows that except that the incidence of the cancer of the normal group is 0, the incidence of the liver cancer of the cancer model group and the ADESe group is 90-100%, and the incidence of the liver cancer is obviously reduced to 50% by supplementing vitamins and Se.
The serum AFP, AFP-L3 levels in surviving rats were measured by ELISA and the results are shown in Table 4:
TABLE 4 levels of AFP, AFP-L3 in various groups of rats
Figure BDA0002181954750000092
Note: in comparison to the cancer model group,aP<0.01; in comparison with the normal group,bP<0.01; in comparison with the ADESe-deficient group,cP<0.01。
compared with the cancer model group, the AFP level of the ADESe-deficient group is obviously increased (P <0.01), and the AFP value of the composition group for surviving rats is obviously lower than that of the ADESe-deficient group and the model group, thereby showing better anti-cancer effect (P < 0.01).
AFP (alpha-fetoprotein) is a protein synthesized by embryonic liver cells, is closely related to abnormal rising of AFP of adults and carcinogenesis, and is clinically commonly used for screening and early diagnosis of liver cancer. But due to the poor specificity of AFP, it is often used in combination with the detection of AFP-L3 (alpha-fetoprotein heteroplasmon) to reduce false positive events. The data analysis shows that the deficiency of vitamin A, vitamin D, vitamin E and trace element selenium can accelerate and aggravate the cancer progression of the primary liver cancer rat, and has obvious promotion effects on the cancer progression and the cancer death rate; and the incidence of cancer can be reduced by properly supplementing deficient vitamin A, vitamin D, vitamin E and trace element selenium.

Claims (7)

1. A composition for assisting in preventing tumors of middle-aged and elderly people comprises 160-800 mu g of vitamin A, 2-15 mu g of vitamin D, 5-150 mu g of vitamin E, 10-100 mu g of selenium and acceptable auxiliary materials.
2. The composition of claim 1, wherein: the content of the vitamin A is 600-800 mu g; the content of the vitamin D is 5-10 mu g; the content of the vitamin E is 10-100 mu g; the selenium content is 20-100 mug.
3. The composition of claim 1, wherein: the vitamin A comprises vitamin A and beta-carotene of plant origin.
4. The composition of claim 1, wherein: the vitamin D comprises vitamin D2 and vitamin D3.
5. The composition of claim 1, wherein: the selenium comprises inorganic selenium and organic selenium, the inorganic selenium comprises sodium selenite and sodium selenate, and the organic selenium comprises selenoprotein, selenium-enriched yeast, selenate lipopolysaccharide, selenium-enriched edible fungi, selenocysteine and selenomethionine.
6. The composition of claim 1, wherein: the composition can be prepared into oral preparations such as common tablets, chewable tablets, soft capsules, hard capsules, powder, granules and the like.
7. Use of the multivitamin and trace element composition of any one of claims 1 to 6 in the preparation of a product for the adjuvant prevention of tumors in the middle-aged and elderly people.
CN201910799644.4A 2019-08-28 2019-08-28 Composition with auxiliary tumor prevention effect Pending CN112438393A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910799644.4A CN112438393A (en) 2019-08-28 2019-08-28 Composition with auxiliary tumor prevention effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910799644.4A CN112438393A (en) 2019-08-28 2019-08-28 Composition with auxiliary tumor prevention effect

Publications (1)

Publication Number Publication Date
CN112438393A true CN112438393A (en) 2021-03-05

Family

ID=74742284

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910799644.4A Pending CN112438393A (en) 2019-08-28 2019-08-28 Composition with auxiliary tumor prevention effect

Country Status (1)

Country Link
CN (1) CN112438393A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115702933A (en) * 2021-08-09 2023-02-17 深圳奥萨制药有限公司 Composition for assisting in reducing blood glucose

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1685976A (en) * 2005-05-08 2005-10-26 颜怀玮 Liposoluble composite vitamin microelement and manufacturing method
CN101485668A (en) * 2008-01-16 2009-07-22 北京汉潮联创中药科技有限公司 Nutriment composite for persons in middle and old age
CN102669682A (en) * 2011-03-08 2012-09-19 上海杰康诺生物科技有限公司 Selenium-enriched nutrient yeast food and production method thereof
CN106942747A (en) * 2017-03-22 2017-07-14 深圳奥萨制药有限公司 A kind of health food for being applied to the elderly
CN108653322A (en) * 2018-07-02 2018-10-16 福州脉趣恒生科技有限公司 A kind of composition with the functional health product for preventing metastases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1685976A (en) * 2005-05-08 2005-10-26 颜怀玮 Liposoluble composite vitamin microelement and manufacturing method
CN101485668A (en) * 2008-01-16 2009-07-22 北京汉潮联创中药科技有限公司 Nutriment composite for persons in middle and old age
CN102669682A (en) * 2011-03-08 2012-09-19 上海杰康诺生物科技有限公司 Selenium-enriched nutrient yeast food and production method thereof
CN106942747A (en) * 2017-03-22 2017-07-14 深圳奥萨制药有限公司 A kind of health food for being applied to the elderly
CN108653322A (en) * 2018-07-02 2018-10-16 福州脉趣恒生科技有限公司 A kind of composition with the functional health product for preventing metastases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115702933A (en) * 2021-08-09 2023-02-17 深圳奥萨制药有限公司 Composition for assisting in reducing blood glucose
CN115702933B (en) * 2021-08-09 2024-04-16 深圳奥萨制药有限公司 Composition for assisting in reducing blood sugar

Similar Documents

Publication Publication Date Title
JP3224767B2 (en) Oral zinc composition
TWI666021B (en) Composition containing oligofructose and quercetin glycoside
EP1938810B1 (en) Ameliorating agent for metabolic syndrome
CN107028191B (en) Vitamin composition suitable for accurate nutrition of middle-aged and elderly people
WO2018077277A1 (en) Chewable tablet containing vitamin c sodium and preparation method thereof
CN108719988B (en) Coenzyme Q10 clathrate and preparation process thereof
JP2016532446A (en) Enbu fermented food or beverage composition
CN106942747A (en) A kind of health food for being applied to the elderly
CN112438393A (en) Composition with auxiliary tumor prevention effect
CN103781371B (en) Solid-like composition
KR101902932B1 (en) A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum
CN106901379B (en) Vitamin health food for assisting in preventing cardiovascular diseases
US20240115644A1 (en) Composition for preventing, improving or treating gastritis or peptic ulcer comprising extract of cinnamomum cassia, fraction of said extract, isolate of said fraction or compounds isolated therefrom
CN106974292B (en) A vitamin composition health food comprising vitamin D, E and folic acid
JP2004059522A (en) Long-acting rutin preparation
CN109588727B (en) Health food for auxiliary prevention of cardiovascular diseases
CN106923346B (en) Selected composite vitamin health product and application thereof
KR102612520B1 (en) Composition for preventing, improving or treating gastritis or gastrointestinal ulcer comprising complex of anthocyanin and anionic polysaccharide
CN107125768B (en) A health food containing vitamins D, E and B12Composed nutrient composition
CN103156105B (en) Solid-like composition
US20240115641A1 (en) Oral film and stick jelly for improving absorption in the oral mucosa, antioxidant activity, anti-inflammatory activity, and liver function of humans and companion animals
KR102462791B1 (en) Oral film and stick jelly composition to improve absorption rate, antioxidant, anti-inflammatory, and liver function in the oral mucosa of humans and pets
KR20100056329A (en) Calcium compound and calcium compound fertilized rice for the prevention and treatment of osteoporosis
EP4327810A1 (en) Lipid decrease promoter
US20220370432A1 (en) Compositions comprising mixtures of compounds and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210305